IP Verse

Crystalline Forms Of A Prolyl Hydroxylase Inhibitor - EP3470397

The patent EP3470397 was granted to Fibrogen on Dec 29, 2021. The application was originally filed on Jul 15, 2013 under application number EP18189607A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3470397

FIBROGEN
Application Number
EP18189607A
Filing Date
Jul 15, 2013
Status
Granted And Under Opposition
Nov 26, 2021
Grant Date
Dec 29, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKSep 29, 2022ELKINGTON AND FIFEADMISSIBLE
SANDOZSep 28, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSSep 28, 2022D YOUNGADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006276477
DESCRIPTIONUS2007004627
DESCRIPTIONUS2007259960
DESCRIPTIONUS4558006
DESCRIPTIONUS4667016
DESCRIPTIONUS7323475
DESCRIPTIONWO2005118836
OPPOSITIONEP1819607
OPPOSITIONEP2872488
OPPOSITIONUS2004254215
OPPOSITIONUS2012067219
OPPOSITIONUS2013068297
OPPOSITIONUS2013083256
OPPOSITIONWO2012097331
OPPOSITIONWO2013013609
OPPOSITIONWO2014014835
SEARCHUS2004254215
SEARCHWO2013013609

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARAVIND; KOONIN, Genome Biol, (20010000), vol. 2-
DESCRIPTION- BRUICK; MCKNIGHT, Science, (20010000), vol. 294, pages 1337 - 1340-
DESCRIPTION- EPSTEIN et al., Cell, (20010000), vol. 107, pages 43 - 54-
DESCRIPTION- KIVIRIKKO; MYLLYLA, Methods Enzymol., (19820000), vol. 82, pages 245 - 304-
DESCRIPTION- TAYLOR, Gene, (20010000), vol. 275, pages 125 - 132-
OPPOSITION- Anonymous, "European Medicines Agency ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE FOR GUIDANCE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES", (20060101), pages 1 - 32, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, (20150904), XP055211303-
OPPOSITION- ANONYMOUS, "ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3B(R2)", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICALREQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, XX, XX, XX , (20060602), vol. 4, pages 1 - 16, XP003033000-
OPPOSITION- Anonymous, "ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURESSANDDACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCESSANDDNEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (19991001), INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20221013), XP055970814-
OPPOSITION- Ema, "EVRENZO", European Medicines Agency Assessment report EMA/CHMP/393136/2021, (20210624), pages 1 - 153, European Medicines Agency Assessment report EMA/CHMP/393136/2021, (20221010), XP055969164-
OPPOSITION- Florence, A. J., "Polymorph screening in pharmaceutical development", European pharmaceutical review, Kent : Russell Publ., US, US , (20100819), no. 4, ISSN 1351-1599, pages 28 - 33, XP009151199-
OPPOSITION- HILFIKER R. , BLATTER F., RAUMER VON M., "Relevance of Solid-state Properties for Pharmaceutical products", HILFIKER R. , BLATTER F., RAUMER VON M., HILFIKER R, WEINHEIM (DE) , WILEY-VCH , (20060101), pages 1 - 19, ISBN 978-3-527-31146-0, XP002525043-
OPPOSITION- Itwg, "Guidelines on Powder X-ray Diffraction (XRD)", Nuclear Forensics International Technical Working Group (ITWG), (20150201), Nuclear Forensics International Technical Working Group (ITWG), URL: http://www.nf-itwg.org/pdfs/ITWG-INFL-PXRD.pdf, (20221010), XP055969165-
OPPOSITION- J .K. GUILLORY, "Generation of polymorphs, hydrates, solvates, and amorphous solids", Polymorphism in Pharmaceutical Solids, (19990000), pages 183 - 226, XP002376368-
OPPOSITION- Mino R. Caira, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY., SPRINGER, BERLIN., DE, DE , (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208, XP001156954
OPPOSITION- W. I. CROSS et al., "A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal", Crystal Growth & Design, (20020000), vol. 3, no. 2, doi:10.1021/cg025589n, pages 151 - 158, XP055518274
OPPOSITION- Stephen Byrn, Pfeiffer Ralph, Ganey Michael, Hoiberg Charles, Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, Springer US, New York, New York, (19950101), vol. 12, no. 7, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP055399407
OPPOSITION- R. HILFIKER et al., "Polymorphism - integrated approach from high-throughput screening to crystallization optimization", Journal of Thermal Analysis and Calorimetry, (20030000), vol. 73, no. 2, doi:10.1023/A:1025409608944, pages 429 - 440, XP002978524

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents